Maxcyte (MXCT) Total Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has 7 years of Total Current Liabilities data on file, last reported at $10.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 19.8% year-over-year to $10.2 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 19.8% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, down 9.56% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $10.2 million, down from $14.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for MXCT reached as high as $18.1 million in Q2 2022 and fell as low as $10.2 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $15.0 million across 5 years, with a median of $15.5 million in 2022.
• Across the five-year window, Total Current Liabilities surged 44.46% in 2022 and dropped 27.08% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $15.4 million in 2022, then climbed by 15.74% to $17.9 million in 2023, then decreased by 11.65% to $15.8 million in 2024, then slipped by 9.56% to $14.3 million in 2025, then decreased by 28.42% to $10.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $10.2 million in Q1 2026, $14.3 million in Q4 2025, and $16.1 million in Q3 2025.